Article
Oncology
Konstantina Psatha, Laxmikanth Kollipara, Elias Drakos, Elena Deligianni, Konstantinos Brintakis, Eustratios Patsouris, Albert Sickmann, George Z. Rassidakis, Michalis Aivaliotis
Summary: The activation of wild-type p53 protein in human lymphoma is a promising therapeutic strategy. An in vitro integrative comparative multi-omics analysis of different lymphoma types before and after p53 activation can shed light on the molecular mechanisms involved. Our findings provide valuable insights into the role of specific proteins and pathways in lymphoma pathogenesis and the global effect of nutlin-3a, which can guide targeted studies on lymphoma progression and resistance.
Article
Biochemistry & Molecular Biology
Tatyana Grigoreva, Aleksandra Sagaidak, Angelina Romanova, Daria Novikova, Aleksander Garabadzhiu, Viacheslav Tribulovich
Summary: The development of chemoresistance in colorectal cancer cells was replicated in vitro by gradually increasing the drug content in the medium, resulting in reduced sensitivity to drugs of different mechanisms of action in resistant cell lines. The cells were found to utilize a universal efflux defense mechanism, which could be partially neutralized by inhibitors of ABC transport proteins, such as P-glycoprotein, confirming its role in chemoresistance.
CHEMICO-BIOLOGICAL INTERACTIONS
(2021)
Article
Oncology
Irene Veneziani, Paola Infante, Elisa Ferretti, Ombretta Melaiu, Cecilia Battistelli, Valeria Lucarini, Mirco Compagnone, Carmine Nicoletti, Aurora Castellano, Stefania Petrini, Marzia Ognibene, Annalisa Pezzolo, Lucia Di Marcotullio, Roberto Bei, Lorenzo Moretta, Vito Pistoia, Doriana Fruci, Vincenzo Barnaba, Franco Locatelli, Loredana Cifaldi
Summary: The study demonstrated that Nutlin-3a could enhance NK cell-mediated killing of neuroblastoma cells by restoring p53 function and increasing ligand expression for NK-ARs. Adoptive transfer of human NK cells into neuroblastoma-bearing mice resulted in tumor shrinkage and improved overall survival. Nutlin-3a also boosted NK cell-mediated cytotoxicity against neuroblastoma spheroids by increasing ligand expression in primary neuroblastoma cells.
CANCER IMMUNOLOGY RESEARCH
(2021)
Article
Physics, Multidisciplinary
Han Zhou, Yi-Zhao Geng, Shi-Wei Yan
Summary: P53 is a tumor suppressor protein that regulates various cellular processes. It is negatively regulated by MDM2, which inhibits its activity. Inhibitors like Nutlin-3a can disrupt the interaction between p53 and MDM2, leading to the activation of p53 pathway and inhibition of tumor growth.
ACTA PHYSICA SINICA
(2023)
Article
Oncology
Antoine Italiano, Wilson H. Miller, Jean-Yves Blay, Jourik A. Gietema, Yung-Jue Bang, Linda R. Mileshkin, Hal W. Hirte, Brian Higgins, Steven Blotner, Gwen L. Nichols, Lin Chi Chen, Claire Petry, Qi Joy Yang, Christophe Schmitt, Candice Jamois, Lillian L. Siu
Summary: Idasanutlin exhibited dose- and schedule-dependent p53 activation in patients with advanced malignancies, leading to durable disease stabilization in some cases. The QD x 5 schedule was chosen for further development based on these findings.
INVESTIGATIONAL NEW DRUGS
(2021)
Article
Cell Biology
Yanyan Chi, Feng Wang, Yana Zhang, Zhengzheng Shan, Weili Tao, Yujin Lian, Dao Xin, Qingxia Fan, Yan Sun
Summary: Apatinib efficiently inhibits the growth of esophageal squamous cell carcinoma by promoting apoptosis, inhibiting proliferation, invasion, epithelial-mesenchymal transition (EMT) and the Akt/mTOR pathway. It also enhances the antitumor effect of chemotherapeutic agents by suppressing metastasis and angiogenesis.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2022)
Article
Oncology
Maria Aparecida da Conceicao de Lira, Marllyn Marques da Silva, Tamiris Alves Rocha, Danielle Feijo de Moura, Erick Caique Santos Costa, Mayara dos Santos Maia, Luciana Scotti, Marcus Tullius Scotti, Maria de Lourdes Lacerda Buril, Eugenia Cristina Pereira, Francisco Carlos Amanajas de Aguiar Junior, Mariane Cajuba de Britto Lira Nogueira, Noemia Pereira da Silva Santos, Emerson Peter da Silva Falcao, Sebastiao Jose de Melo
Summary: The study evaluated the antitumour potential of a depsidone isolated from Parmotrema concurrens, salazinic acid (SAL), through in vitro, in vivo, and in silico studies. The results demonstrated that SAL showed low cytotoxicity to cancer cell lines and had high tumour inhibition activity in both in vitro and in vivo experiments. Molecular dynamics simulations revealed that SAL had stronger enzymatic interaction capacity with human thymidylate synthase compared to 5-fluorouracil. The findings suggest that salazinic acid has potential as a tumour inhibition agent.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
(2023)
Article
Chemistry, Inorganic & Nuclear
Michaela Balogova, Shubham Sharma, Paulina Cherek, Sigurjon N. Olafsson, Sigridur Jonsdottir, Helga M. Ogmundsdottir, Krishna K. Damodaran
Summary: Organotin complexes, especially Sn-DBPTF-1, show promising cytotoxic effects against various cancer cell lines, inducing apoptosis and cell cycle arrest through DNA damage.
DALTON TRANSACTIONS
(2022)
Article
Pharmacology & Pharmacy
Diana Duarte, Soraia Falcao, Iouraouine El Mehdi, Miguel Vilas-Boas, Nuno Vale
Summary: The study evaluated the anti-cancer efficacy of honeybee venom in combination with chemotherapeutic or CNS drugs in colon and breast cancer cells. The results showed that the combination of honeybee venom with these drugs can improve their anti-cancer activity, especially at lower concentrations.
Article
Oncology
Quentin Bailleul, Pauline Navarin, Melanie Arcicasa, Christine Bal-Mahieu, Angel Montero Carcaboso, Xuefen Le Bourhis, Alessandro Furlan, Samuel Meignan, Pierre Leblond
Summary: Despite the poor prognosis of children with high-grade glioma or diffuse intrinsic pontine glioma, Evofosfamide (Evo) has shown significant preclinical and clinical activities against adult glioblastoma. This study investigated Evo's potential in pediatric glioma cell lines, demonstrating inhibition of cell growth under hypoxia and synergism with commonly used pediatric oncology drugs. Evo also appeared to enhance the effect of ionizing radiations, suggesting it as a promising therapeutic option for children with brain tumors.
Article
Medicine, Research & Experimental
Nair Lopes, Christian Holst Bergsland, Merete Bjornslett, Teijo Pellinen, Aud Svindland, Arild Nesbakken, Raquel Almeida, Ragnhild A. Lothe, Leonor David, Jarle Bruun
LABORATORY INVESTIGATION
(2020)
Article
Oncology
Andreas M. Hoff, Sigrid M. Kraggerud, Sharmini Alagaratnam, Kaja C. G. Berg, Bjarne Johannessen, Maren Holand, Gro Nilsen, Ole C. Lingjaerde, Peter W. Andrews, Ragnhild A. Lothe, Rolf Skotheim
ENDOCRINE-RELATED CANCER
(2020)
Article
Medicine, General & Internal
Jorgen Smeby, Kushtrim Kryeziu, Kaja C. G. Berg, Ina A. Eilertsen, Peter W. Eide, Bjarne Johannessen, Marianne G. Guren, Arild Nesbakken, Jarle Bruun, Ragnhild A. Lothe, Anita Sveen
Article
Multidisciplinary Sciences
Iwona Grad, Robert Hanes, Pilar Ayuda-Duran, Marieke Lydia Kuijjer, Jorrit M. Enserink, Leonardo A. Meza-Zepeda, Ola Myklebost
Summary: Drug testing on liposarcoma cells has identified six potential anti-cancer drugs that target different mechanisms and have low toxicity to normal cells. These drugs show promise for the treatment of liposarcoma.
Article
Biochemistry & Molecular Biology
Marianne Stabell, Thomas Saether, Asmund K. Rohr, Odd S. Gabrielsen, Ola Myklebost
Summary: Through methylation of a lysine residue in the KAE SUMOylation motif of HMGA2, the sequence is transformed into a consensus SUMO motif, leading to increased SUMOylation at that site. Similar methylation-dependent SUMO motifs are found in other chromatin factors, suggesting that crosstalk between methylation and SUMOylation is a general mode for regulating chromatin function.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Pathology
Tatiana Georgiesh, Heidi Maria Namlos, Nitin Sharma, Susanne Loren, Ola Myklebost, Bodil Bjerkehagen, Leonardo A. Meza-Zepeda, Kjetil Boye
Summary: This study found that NAB2-STAT6 fusion variants are associated with distinct clinicopathological and molecular characteristics in solitary fibrous tumour patients, and have prognostic significance in extrameningeal SFT.
Article
Oncology
Sigve Nakken, Vladislav Saveliev, Oliver Hofmann, Pal Moller, Ola Myklebost, Eivind Hovig
Summary: High-throughput germline genetic testing is increasingly valuable in cancer care, and the open-source CPSR computational workflow can generate structured reports highlighting the therapeutic, prognostic, and diagnostic relevance of germline variants in cancer predisposition genes. The tool provides flexibility in selecting genes to include in the report, while maintaining consistency with ACMG standards.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Multidisciplinary Sciences
Peter Peneder, Adrian M. Stutz, Didier Surdez, Manuela Krumbholz, Sabine Semper, Mathieu Chicard, Nathan C. Sheffield, Gaelle Pierron, Eve Lapouble, Marcus Totzl, Bekir Erguner, Daniele Barreca, Andre F. Rendeiro, Abbas Agaimy, Heidrun Boztug, Gernot Engstler, Michael Dworzak, Marie Bernkopf, Sabine Taschner-Mandl, Inge M. Ambros, Ola Myklebost, Perrine Marec-Berard, Susan Ann Burchill, Bernadette Brennan, Sandra J. Strauss, Jeremy Whelan, Gudrun Schleiermacher, Christiane Schaefer, Uta Dirksen, Caroline Hutter, Kjetil Boye, Peter F. Ambros, Olivier Delattre, Markus Metzler, Christoph Bock, Eleni M. Tomazou
Summary: The study introduces an integrated genetic/epigenetic analysis method for liquid biopsy of pediatric tumors with few genetic aberrations. The LIQUORICE algorithm is developed for detecting and classifying circulating tumor DNA based on cancer-specific chromatin signatures. The research highlights the potential value of cfDNA fragmentation patterns as prognostic biomarkers in Ewing sarcoma and makes liquid biopsy benefits more accessible for childhood cancers.
NATURE COMMUNICATIONS
(2021)
Article
Genetics & Heredity
Anita Sveen, Bjarne Johannessen, Ina A. Eilertsen, Bard Rosok, Marie Gulla, Peter W. Eide, Jarle Bruun, Kushtrim Kryeziu, Leonardo A. Meza-Zepeda, Ola Myklebost, Bjorn A. Bjornbeth, Rolf Skotheim, Arild Nesbakken, Ragnhild A. Lothe
Summary: Only a subset of mutations in microsatellite stable colorectal cancers were expressed, and the expressed mutation dose may provide an opportunity for more fine-tuned biomarker interpretations.
Article
Biotechnology & Applied Microbiology
Heidi M. Namlos, Magne Skarn, Deeqa Ahmed, Iwona Grad, Kim Andresen, Stine H. Kresse, Else Munthe, Massimo Serra, Katia Scotlandi, Antonio Llombart-Bosch, Ola Myklebost, Guro E. Lind, Leonardo A. Meza-Zepeda
Summary: miR-486-5p is an epigenetically regulated miRNA in osteosarcoma, playing a significant role in the biology of the disease.
Article
Oncology
Kristine Misund, Davine Hofste Op Bruinink, Eivind Coward, Remco M. Hoogenboezem, Even Holth Rustad, Mathijs A. Sanders, Morten Rye, Anne-Marit Sponaas, Bronno van der Holt, Sonja Zweegman, Eivind Hovig, Leonardo A. Meza-Zepeda, Anders Sundan, Ola Myklebost, Pieter Sonneveld, Anders Waage
Summary: We investigated the genomic and transcriptomic changes in multiple myeloma patients before and after treatment. The study discovered changes in clonal composition and increased single-nucleotide variants. It also found alterations in specific genes and pathways, such as RAS genes, amp1q21, and TP53, and identified increased expression of potentially targetable genes in late-stage disease.
Article
Genetics & Heredity
Andreas Venizelos, Christina Engebrethsen, Wei Deng, Jurgen Geisler, Stephanie Geisler, Gjertrud T. Iversen, Turid Aas, Hildegunn S. Aase, Manouchehr Seyedzadeh, Eli Sihn Steinskog, Ola Myklebost, Sigve Nakken, Daniel Vodak, Eivind Hovig, Leonardo A. Meza-Zepeda, Per E. Lonning, Stian Knappskog, Hans P. Eikesdal
Summary: Subclonal composition of treatment-naive breast cancers undergoes profound changes during neoadjuvant chemotherapy with epirubicin and docetaxel monotherapy, while early truncal mutations and major subclones generally persist through treatment. Tumor mutational burden decreases during neoadjuvant therapy.
Meeting Abstract
Hematology
Baoyan Bai, Jillian F. Wise, Daniel Vodak, Sigve Nakken, Ankush Sharma, Yngvild Nuvin Blaker, Marianne Brodtkorb, Vera Hilden, Gunhild Troen, Weicheng Ren, Suzanne Lorenz, Michael S. Lawrence, Ola Myklebost, Eva Kimby, Qiang Pan-Hammarstrom, Leonardo Meza-Zepeda, Klaus Beiske, Erlend B. Smeland, Eivind Hovig, Ole Christian Lingjaerde, Harald Holte, June Helen Myklebust
Article
Multidisciplinary Sciences
Mandy L. Ballinger, Swetansu Pattnaik, Piyushkumar A. Mundra, Milita Zaheed, Emma Rath, Peter Priestley, Jonathan Baber, Isabelle Ray-Coquard, Nicholas Isambert, Sylvain Causeret, Winette T. A. van der Graaf, Ajay Puri, Florence Duffaud, Axel Le Cesne, Beatrice Seddon, Coonoor Chandrasekar, Joshua D. Schiffman, Andrew S. Brohl, Paul A. James, Jean-Emmanuel Kurtz, Nicolas Penel, Ola Myklebost, Leonardo A. Meza-Zepeda, Hilda Pickett, Maya Kansara, Nicola Waddell, Olga Kondrashova, John Pearson, Andrew P. Barbour, Shuai Li, Tuong L. Nguyen, Diane Fatkin, Robert M. Graham, Eleni Giannoulatou, Melissa J. Green, Warren Kaplan, Shyamsundar Ravishankar, Joseph Copty, Joseph E. Powell, Edwin Cuppen, Kristel van Eijk, Jan Veldink, Jin-Hee Ahn, Jeong Eun Kim, R. Lor Randall, Kathy Tucker, Ian Judson, Rajiv Sarin, Thomas Ludwig, Emmanuelle Genin, Jean-Francois Deleuze, Michelle Haber, Glenn Marshall, Murray J. Cairns, Jean-Yves Blay, David M. Thomas
Summary: Cancer genetics has focused on epithelial malignancies, but this study explores specific pathways related to sarcomas, rare malignancies derived from embryonic mesoderm. Germline sequencing of sporadic cases and healthy controls reveals two sarcoma-specific pathways involved in mitotic and telomere functions. Centrosome gene variants are linked to specific tumors, while heritable defects in the shelterin complex increase susceptibility to sarcomas, melanomas, and thyroid cancers. These findings highlight the role of heritable defects in mitotic and telomere biology in sarcoma risk.
Article
Oncology
Heidi Maria Namlos, Ksenia Khelik, Sigve Nakken, Daniel Vodak, Eivind Hovig, Ola Myklebost, Kjetil Boye, Leonardo A. Meza-Zepeda
Summary: Patients with localised, high-risk gastrointestinal stromal tumours (GIST) who receive adjuvant imatinib treatment may still relapse within 3 years. Current risk classification methods are not accurate in predicting poor outcomes after standard treatment. This study aimed to identify genomic and transcriptomic profiles associated with disease relapse and a more aggressive phenotype. The findings suggest that increased chromosomal instability is an intrinsic feature for metastasizing tumours and could serve as a novel prognostic biomarker for high-risk GIST.
MOLECULAR ONCOLOGY
(2023)